Integrin Ligand Conjugates for Serum-Stable Tumor Cargo Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for stable and effective targeting compounds that can selectively bind to integrin alpha-v beta-3 and alpha-v beta-5 to facilitate the delivery of therapeutic cargo molecules, such as oligonucleotide-based compounds, to specific cells or tissues, particularly tumor cells, as existing inhibitors like Cilengitide have shown limited efficacy in clinical trials.
Innovation Solution
Development of integrin targeting ligands that exhibit affinity for integrin alpha-v beta-3 and alpha-v beta-5, which are conjugated to cargo molecules like RNAi agents, enabling selective delivery to cells expressing these integrins, thereby inhibiting target gene expression and treating diseases like clear cell renal carcinoma.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing integrin inhibitors like Cilengitide are used, then integrin alpha-v beta-3 binding affinity is achieved, but clinical efficacy is insufficient
Solution Approach 1:
The patent modifies the chemical structure of integrin targeting ligands by changing parameters such as molecular weight, functional groups, and conjugation methods to enhance both binding affinity and clinical efficacy. The ligands are designed with optimized pharmacological properties that resolve the contradiction between strong binding and clinical effectiveness.
Solution Approach 2:
The patent creates composite targeting compounds by conjugating integrin ligands with cargo molecules (such as oligonucleotide-based therapeutics, antibodies, or nanoparticles). This composite approach allows the ligand to maintain high binding affinity while the conjugated cargo provides the therapeutic effect, thereby achieving both strong binding and clinical efficacy simultaneously.
2Measurement precision
If targeting compounds are designed to bind specifically to integrin alpha-v beta-3, then delivery specificity to tumor cells is improved, but stability in serum may be compromised
Solution Approach 1:
The patent introduces stable linkers and conjugation intermediaries between the integrin ligand and cargo molecule. These intermediaries act as bridges that maintain the specificity of integrin binding while providing serum stability. The linkers are designed to resist degradation in serum while preserving the binding interface integrity.
Solution Approach 2:
The patent optimizes the chemical and physical parameters of the targeting compound, including molecular size, charge distribution, and structural rigidity, to achieve both high delivery specificity to integrin alpha-v beta-3 and enhanced serum stability. The compounds are designed with pharmacological properties that prevent premature degradation while maintaining target recognition.
3Productivity
If oligonucleotide-based compounds are conjugated to integrin ligands, then delivery to integrin-expressing cells is facilitated, but manufacturing complexity increases
Solution Approach 1:
The patent divides the conjugate system into separate modular components: the integrin ligand, the linker, and the oligonucleotide cargo. This segmentation allows for independent optimization and simplified manufacturing of each component, which can then be assembled through standardized conjugation protocols, reducing overall manufacturing complexity while maintaining high delivery efficiency.
Solution Approach 2:
The patent employs stable linkers as intermediaries that simplify the conjugation process between oligonucleotide-based compounds and integrin ligands. These linkers provide standardized attachment points that facilitate efficient conjugation while maintaining the functional integrity of both components, thereby improving delivery efficiency without proportionally increasing manufacturing complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The integrin targeting ligands provide stable and specific delivery of therapeutic cargo molecules to integrin-expressing cells, effectively inhibiting target gene expression and treating various cancers in vivo.
Implementation Method 1
The integrin targeting ligands disclosed herein have affinity for, and can bind with specificity to, these integrins
Data Source
AI summary
Compounds having affinity for integrins, the synthesis of these compounds, and the use of these compounds as ligands to facilitate the delivery of cargo molecules to cells expressing integrins are described. The described integrin targeting ligands have serum stability and affinity for ανβ3 integrin and/or ανβ5 integrin, and are suitable for conjugation to cargo molecules, such as such as oligonucleotide-based therapeutic agents (e.g., RNAi agents), to facilitate delivery of the cargo molecules to cells and tissues, such as tumor cells, that express integrin ανβ3, integrin ανβ5, or both integrin ανβ3 and integrin ανβ5. Compositions that include integrin targeting ligands and methods of use are also described.